Zhengye Biotechnology (ZYBT) Competitors

Zhengye Biotechnology (NASDAQ:ZYBT) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.

Is ZYBT or ANIP more profitable?

Zhengye Biotechnology has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Zhengye Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
ANI Pharmaceuticals	-1.28%	15.87%	6.88%

Do institutionals & insiders have more ownership in ZYBT or ANIP?

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to ZYBT or ANIP?

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 3 mentions for Zhengye Biotechnology. ANI Pharmaceuticals' average media sentiment score of 1.58 beat Zhengye Biotechnology's score of 0.62 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has preferable earnings & valuation, ZYBT or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$189.75M	1.73	N/A	N/A	N/A
ANI Pharmaceuticals	$674.07M	2.02	$18.78M	-$1.27	-49.43

Does the MarketBeat Community prefer ZYBT or ANIP?

ANI Pharmaceuticals received 441 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users.

Company	Underperform	Outperform
Zhengye Biotechnology	N/A	N/A
ANI Pharmaceuticals	Outperform Votes 441 64.19%	Underperform Votes 246 35.81%

Do analysts rate ZYBT or ANIP?

ANI Pharmaceuticals has a consensus target price of $80.13, indicating a potential upside of 27.63%. Given ANI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

ANI Pharmaceuticals beats Zhengye Biotechnology on 13 of the 14 factors compared between the two stocks.